Life Sciences Blueprint - nursingtimes.net · 2 Life Sciences Blueprint As set out in “Building...

Life Sciences BlueprintA statement from the Office for Life SciencesJuly 2009

Front cover photograph supplied courtesy of A Cavanagh, Wellcome Images. Scanning electron micrograph of Purkinje neurons. 2008.

Many of the policies and statements set out in this Blueprint extend over the whole United Kingdom, but for some, responsibility is devolved in Northern Ireland, Scotland and Wales. Thus, not all commitments will automatically apply across the UK. We will work closely with the Devolved Administrations, respecting their responsibilities and administrative structures, towards the goals of promoting and supporting a thriving life sciences industry in the UK.

Following the launch of this Blueprint, there will be a programme of work leading to the publication of a delivery plan in the autumn, accompanied by a full impact assessment detailing the costs and benefits for policy proposals.

Office forLife Sciences

2

Life Sciences Blueprint

As set out in “Building Britain’s Future”, we will build tomorrow’s economy by investing today in those high-tech industries of the future where the UK has competitive advantage and the potential to be a global leader. The strategy set out in New Industry, New Jobs will be key part of this, by supporting business, innovation and entrepreneurship. The life sciences industry,

comprising pharmaceuticals, medical biotechnology and medical technology, is one industry where we are world-class, and have the potential to go further. A strong life sciences industry can drive growth and high-value job creation as well as playing a vital role in meeting future healthcare challenges.

The UK has solid foundations to build on, with its National Health Service, the substantial investment in the research base over the last 10 years, and a highly-skilled workforce. But we need to do more to ensure that the UK continues to offer an attractive environment for life sciences companies to do business. The Government has a crucial role to play, helping to remove the barriers that prevent the UK from making the most of its strengths.

In establishing the Office for Life Sciences, the Government clearly signalled the importance of the industry to building the Britain of the future. The Office, under Lord Drayson’s leadership, has been an early exemplar of the Government’s active approach to industrial policy. This Blueprint sets out those actions, which together form a package of measures that has the potential to transform the UK for the life sciences industry. In particular:

creating of an “Innovation Pass” that will give patients faster access to ●●

cutting-edge medicines;

measures to ensure the NHS leads the way in the uptake of ground-●●

breaking and cost-effective medicines and technologies;

accrediting biosciences degrees to ensure graduates leave with the skills ●●

required by industry; and

supporting the formation of an internationally-recognised UK Life Sciences ●●

Super Cluster.

We are grateful to all those, in Government and in industry, who have devoted time and effort to making the Office a success. In particular, we would like to thank the industry chairs of the four working groups, David Brickwood, Subhanu Saxena, John Aston and Chris Brinsmead, and the industry trade associations, ABPI, BIA, ABHI and BIVDA, who have been central to rapidly bringing the industry together to work as one with Government.

Lord Mandelson First Secretary of State, Secretary of State for Business, Innovation & Skills

Foreword

Andy Burnham Secretary of State for Health

3

PrefaceIn January 2009, the Prime Minister held a summit meeting with global representatives of the life sciences industry. At the summit, industry emphasised the need to take action to support the UK life sciences industry as a major growth industry of the future, to help ensure the UK’s place as a global leader. In response, the Government created the Office for Life Sciences (OLS) led by Lord Drayson, Minister for Science and Innovation.

The OLS has created a new way of working, across Government and industry, requiring a fresh perspective from industry as much as from Government. For example, Government and industry need to work together to build on the NHS Next Stage Review and enshrine the NHS as an engine of innovation. This should be complemented by action to ensure that there is investment in innovative companies to carry through the innovation driven by our Research Councils and universities.

For the life sciences industry, the new way of working has offered great opportunities. For the first time, the industry is speaking with a single voice, bringing together the pharmaceutical, medical biotechnology, and medical technology sectors in a single forum.

The OLS process has required the life sciences industry not just to articulate the challenges facing the industry in the UK, but to work in partnership with Government and other key stakeholders to plan novel solutions.

This Life Sciences Blueprint is the culmination of six months’ focussed work between industry and Government. Demonstrating real change is dependent on both industry and Government continuing to work together to deliver tangible results through the actions set out in this Blueprint.

David Brickwood Subhanu Saxena John Aston Chris Brinsmead Johnson and Johnson Novartis Astex Therapeutics AstraZeneca

5

Contents

Summary of key actions 6

Chapter 1: Life sciences – an industry of vital importance to the UK 8

Chapter 2: The NHS as an innovation champion 12

Chapter 3: Building a more integrated life sciences industry 18

Chapter 4: Access to finance and stimulating investment 22

Chapter 5: Marketing UK life sciences 26

Next steps 28

Annex: Life Sciences Action Plan 30

Annex: Membership of the Office for Life Sciences working groups 42

6

Summary of key actions

The Office for Life Sciences has developed a package of actions to transform the UK environment for life sciences companies. These actions have been agreed across Government, and with industry, the Higher Education sector and the NHS.

The key actions contained in this Blueprint are listed below. A full list is set out in the Life Sciences Action Plan at the end of this document.

The NHS as an innovation champion

The Government, with the National Institute for Clinical Excellence (NICE), will 1. introduce an ”Innovation Pass”, making selected innovative medicines available on the NHS for a time-limited period. The Pass will be piloted in 2010/2011, with a budget of £25 million. At the end of the pilot year, the Government will evaluate the pilot before setting out the budget for the remaining two years of the initiative.

The Government will create a Strategic Health Authority (SHA) Delivery 2. Group to improve both uptake of innovative medicines and technologies, and engagement between industry and the NHS.

The NHS Chief Executive will review system levers and incentives, including 3. Payment By Results, to accelerate the uptake of medical technologies.

The Government will reinforce the need for greater emphasis on research and 4. clinical trials in the next NHS Operating Framework, building on the existing commitment to include numbers of patients in clinical research in the metrics which Trusts report in their Quality Accounts.

Building a more integrated life sciences industry

From 2010, the Society of Biology will begin to accredit undergraduate 5. bioscience degrees to help ensure that graduates leave with the core mathematical and practical skills and competencies required by employers.

The Government, together with industry and the Higher Education sector, will 6. create a forum to address skills gaps.

The Government will support the formation of a UK Life Sciences Super Cluster 7. to co-ordinate work across industry, Higher Education and the NHS, and to boost international recognition of UK life sciences.

7

Access to finance and stimulating investment

On 29 June 2009, the Government announced the creation of a UK Innovation 8. Investment Fund to invest in technology-based businesses with high-growth potential, including life sciences companies. The Government will invest £150 million alongside private sector investment on an equal basis, with the aim of leveraging enough private investment to build a £1 billion, 10-year Venture Capital fund.

Budget 2009 announced that the Government would consider evidence for 9. further changes to the way the tax system encourages innovative activity, to ensure the ongoing competitiveness of the UK. The Government will set out its assessment and proposed approach before the 2009 Pre-Budget Report.

The Technology Strategy Board will launch an £18 million “RegenMed” 10. programme of investment to support key areas of commercial R&D and the development of R&D partnerships. The Medical Research Council, the Engineering and Physical Sciences Research Council, and the Biotechnology and Biological Sciences Research Council who will provide additional funding of at least £3.5 million.

The Technology Strategy Board has also committed to increase its expertise in the life sciences.

Marketing UK life sciences

The Government, through UKTI, will invest £1 million from the Strategic 11. Investment Fund to further promote the UK and NHS brands at flagship life sciences events in the UK and overseas.

The Office for Life Sciences and UK Trade and Investment will hold a series 12. of roadshows throughout the English regions and Devolved Administrations, beginning in September. These roadshows will bring together businesses with other key regional stakeholders to:

Discuss the Blueprint commitments and next steps to implement them; (i) and

Help ensure the UK life sciences industry speaks with one consistent (ii) voice in its global marketing activities.

8

Chapter 1

Life sciences – an industry of vital importance to the UK

The UK is a world leader in life sciences (pharmaceuticals, medical 1.1 biotechnology, and medical technology). Life sciences is one of the high-tech strategic industries that will play a vital role in: building a stronger Britain of the future; driving growth and prosperity as well as continuing improvements in healthcare delivery; and meeting future challenges such as an ageing population and obesity.

The UK ranks second in the world after the US and has established itself 1.2 in future growth areas such as regenerative and stratified medicine. The pharmaceutical sector is the leading sector for investment in research and development (R&D), investing £4.5bn in R&D in the UK in 2007 alone, representing over a quarter of all UK business R&D1. The UK medical biotechnology sector leads Europe in the number of drugs in all stages of clinical development2. The medical technology sector is growing rapidly with the largest share in Europe at just over 2,000 companies, the majority of which are small and medium enterprises (SMEs), and the sector collectively employs almost 50,000 people across the UK3.

Our shared vision is for a life sciences industry which is able to make the best 1.3 possible contribution to the future wealth of the country and to continued improvement in health and wellbeing for the UK and globally; focuses its entrepreneurial effort on areas of greatest scientific potential as well as greatest healthcare need; combines cutting edge R&D with a core manufacturing capability; and operates increasingly through symbiotic relationships between small and large companies, and between industry and Higher Education and healthcare providers.

Meeting future challenges will drive growth in the industry and offers the 1.4 opportunity to consolidate the UK’s global leadership and attract increased investment from UK and overseas companies. As a location for life sciences companies, the UK has considerable strengths to build on. A key factor in past successes has been the translation of basic science into commercially successful products. The UK’s world-class science base, based in globally recognised universities and research establishments, will continue to be a cornerstone of progress in UK life sciences in the future. This will be underpinned by investment in the UK’s overall research base, which has increased steadily over the past 10 years and will rise to almost £6 billion a year by 2010.

1 http://www.dius.gov.uk/innovation/statistics_and_analysis/randd_scoreboard/~/media/publications/2/2008_RD_Scoreboard_analysis

2 “Beyond borders. Global biotechnology report 2009”. Ernst and Young. 3 http://www.berr.gov.uk/whatwedo/sectors/biotech/healthtech/page41607.html

9

The NHS is a unique selling point for the UK, and has the potential to add 1.5 significantly to the UK’s attractiveness as a base for life sciences, providing high-quality healthcare to all, and offering a competitive advantage with its vast patient databases for clinical trials and investigations. There is also a vital role for the NHS as a value-creator and an engine of economic growth, leading the way in the uptake of innovative medicines and technologies, deepening collaboration with industry, and helping the industry to flourish and grow. In turn, a flourishing life sciences industry will help generate the step-change innovation needed to maintain quality of services and productivity into the future.

However, the UK’s leadership position is threatened and the life sciences 1.6 industry is facing a number of challenges which must be addressed if it is to fulfil its potential as a major driver of growth. The UK’s share of global patient enrolment in clinical trials has dropped from 6% in 2000 to 2% in 20064. The pharmaceutical sector is facing a patent “cliff”, equivalent to $140 billion in sales, as several blockbuster drugs come off patent over the next few years, and must in any case look to new business models to replenish its pipeline. For medical biotechnology companies, the continuing challenge in accessing finance places at risk the future pipeline of these innovative companies and has the potential to limit growth across this sector. In addition, business and leadership skills are vital to the commercial success of the SMEs that make up the majority of companies. Such skills are also crucial for medical technology companies, as is a mechanism for building relationships with clinicians within the NHS to support the development of new and innovative medical technologies.

To secure its future as the location of choice for life sciences companies, the 1.7 UK needs to do more. The life sciences is a global business and companies take a global view when choosing where to locate activity and jobs. The UK is facing increasing competition from European neighbours and from Asia, with countries taking specific steps to attract life sciences companies. Only by making the most of its strengths will the UK be able to achieve its vision for a diverse and integrated life sciences sector which sustains high-value added employment, and drives economic growth and improved health and wellbeing.

Both Government and industry must take action. Government action, or 1.8 inaction, shapes the conditions in which UK businesses operate. This presents the Government with an opportunity to use policy levers, such as health, skills and fiscal policies, to improve the environment in which UK life sciences companies do business. The Government, through the NHS, is the largest UK customer of medicines and technologies and therefore has a unique opportunity to be at the forefront of innovative procurement, bringing patient and cost benefits. Industry also has a vital role to play in championing the UK’s strengths, clearly articulating where improvement is needed, and working with Government to develop solutions.

4 Centre for Medicines Research International

10


Recognising the importance of the industry to the future of the UK, and the role 1.9 that Government can play in creating an environment in which the industry can flourish, the Prime Minister announced in January the creation of the Office for Life Sciences (OLS), under the leadership of Lord Drayson, Minister for Science and Innovation. The OLS was tasked, over six months, with developing a package of measures which would turn around negative trends, improve the operating environment for UK life sciences companies, and build a sustainable and integrated industry in the future.

The OLS is an early exemplar of the Government’s active approach to 1.10 industrial policy and has demonstrated a new way of working, bringing together Government departments (Business Innovation and Skills; Health; and the Treasury) and industry, through four industry-chaired working groups. By holding weekly meetings, the working groups have been able to rapidly articulate and prioritise the issues, consider the evidence and develop solutions across four key areas:

The NHS as an innovation champion●●

Building a more integrated life sciences industry●●

Access to finance and stimulating investment●●

Marketing the UK life sciences industry overseas●●

This Blueprint sets out the package of actions Government is taking across 1.11 these four pillars to support the UK life sciences industry. The next steps for the Office for Life Sciences are set out at the end of this Blueprint.

11

Life sciences – an industry of vital importance to the UK

12

Chapter 2


The NHS is the largest UK customer of medicines and technologies 2.1 produced by life sciences companies. If this industry is to fulfil its potential as a major growth industry of the future, driving economic growth and prosperity, it is vital that the NHS values and uses cost-effective innovations, and provides an excellent environment for clinical trials and investigations.

A number of initiatives have already improved the NHS environment. 2.2 High Quality Care for All 5 placed an emphasis on innovation, further measures to support uptake of medicines and the creation of a new evaluation pathway for medical technologies. In the 10 years since its inception, the National Institute for Health and Clinical Excellence (NICE) has established itself as a world-leader in health technology appraisal, and its work is influential in healthcare systems around the world. However, industry, NICE and the Government agree that further steps need to be taken to ensure that ongoing research and innovation are promoted.

Flexible pricing and a more systematic approach to patient access schemes 2.3 are part of the new Pharmaceutical Price Regulation Scheme (PPRS) and offer new opportunities to promote cost-effective access to new drugs. The PPRS also includes, for the first time, an innovation package to increase the uptake of cost-effective medicines. The partnerships between the Health Departments and the National Institute for Health Research (NIHR) and stakeholders via the UK Clinical Research Collaboration (UKCRC) and the Office for Strategic Co-ordination of Health Research (OSCHR) have made important advances in developing infrastructure and processes. These partnerships support strategies and policies on research and development (R&D) in the NHS as outlined in Best Research for Best Health 6.

This is by no means an exhaustive list of the work programme in place that 2.4 continues to improve the NHS environment. However, it has become clear that further progress needs to be made to support the life sciences industry to ensure it can play a vital role in delivering improved healthcare in the future.

5 http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085825

6 http://www.dh.gov.uk/en/Researchanddevelopment/Researchanddevelopmentstrategy/DH_4127109

13

Issue2.5 – Whilst most significant new medicines should continue to go through NICE’s existing processes, there will be drugs for small patient populations which have the potential to deliver improved patient outcomes but where data to demonstrate cost-effectiveness is so far limited, and market access may therefore be inhibited, mainly because of the small numbers of patients, and other clinical factors.

OLS solution – The Government, with NICE, will introduce an “Innovation Pass”. This will be a three-year initiative for selected medicines, which will be funded for time-limited use across the NHS, from a new ring-fenced budget, without going through a NICE appraisal. NICE will play a key role in developing and applying eligibility criteria for the Pass. This will give earlier access to innovative drugs for patients with the greatest need. The Pass will be piloted with a budget of £25 million in 2010/2011. The pilot will be developed with input from industry, NICE and the NHS and will be the subject of a consultation by November 2009. Funding for future years will also be discussed through the consultation and will then be determined in the context of the next spending review.

Issue2.6 – There is scope for a more constructive and appropriate dialogue between industry, NICE and the assessment teams whose work supports NICE appraisals.

OLS solution – Companies with medicines and technologies that are being appraised by NICE will be able to attend NICE appraisal committee meetings to respond to any questions from the committee, and will have an opportunity to comment on matters of factual accuracy. At the end of a NICE appraisal, manufacturers will be provided with the opportunity to have a debriefing meeting with NICE, and Evidence Review Groups will be asked to attend scoping meetings for NICE Single Technology Appraisals. The NICE Board has already agreed these actions.

Issue2.7 – There is a question over whether NICE’s methodologies take into account a wide enough range of factors in determining cost-effectiveness, and whether NICE explains clearly enough to the company and other stakeholders the impact that particular factors have had on its decisions.

OLS solution – Sir Ian Kennedy is conducting a study to identify the aspects of value and innovation that NICE should take into account in its work. His report will be published on 22 July 2009. NICE will conduct a one-month public consultation on its response to the Kennedy report in September 2009, and this issue will continue to be an important part of the OLS work programme into the autumn. From November 2009, NICE will also implement improvements in the way in which it explains the impact of specific factors in its decision-making.

14


Issue2.8 – The adoption and uptake of new medicines and technologies in the NHS is variable and in some cases, far behind that of other European countries.

OLS solution – A package of measures to address the uptake issue:

By November 2009, the Government will establish a Strategic Health (a) Authority (SHA) Delivery Group which will be chaired by an SHA Chief Executive. The Delivery Group will work to:

Increase the uptake of cost effective drugs;(i)

Improve the strategic relationship between the NHS and industry so that (ii) both can work together better in a more business-to-business manner;

Improve the competitiveness of the UK as a site for clinical research; and(iii)

Put in place equivalent NHS-led arrangements to support the early and (iv) systematic uptake of innovations in technologies which provide value to the NHS.

The Government will continue work on existing and proposed metrics (b) to provide an authoritative comparison of the uptake of cost-effective medicines, both within the NHS and on an international basis. It will also develop, by autumn 2010, a pilot set of metrics against which NHS organisations can assess themselves in relation to the uptake of cost-effective innovative technologies.

The Government will ensure that at least two of the new Commercial (c) Support Units (CSUs) to be set up, under the new NHS Commercial Operating Model, will develop and test regional approaches to support innovations from the medical technology sector, through engagement with NHS at an early stage of product development.

The Government will work with the NHS to build innovation into the (d) education commissioning system and, by autumn 2009, will provide guidance on what SHA commissioners can do to achieve this.

Issue2.9 – There is an opportunity and a need for radical action to bring priority and pace to the NHS initiatives to improve quality, innovation, productivity, and prevention – to which the life sciences industry makes a very significant contribution.

OLS solution – The NHS Chief Executive is putting in place a package of measures:

The NHS Chief Executive will take personal responsibility for the NHS (a) programme of action to drive greater quality, innovation, productivity, and prevention (QIPP);

15


The NHS Management Board will delegate oversight of the day-to-day (b) running of NHS operational issues to a new NHS Operations Board, leaving the Management Board to focus exclusively on the operational issues of the QIPP agenda;

There will be a major engagement process throughout the healthcare (c) system, with the Board of every NHS organisation expected to engage with staff, industry – including the life sciences industry – and other partners on how innovation can best be harnessed to improve quality and reduce costs at all levels of the system;

The ideas generated by this process will inform the NHS Operating (d) Framework for 2010-2011;

Simultaneously the NHS Chief Executive will also lead a review of system (e) levers and incentives, such as Payment By Results (PBR), and how they might be better deployed to accelerate QIPP; and

The NHS Leadership Council will take steps to intensify the sharing of skills (f) and experience with industry leaders to support more strategic collaboration to drive innovation and bring benefits to patients.

Issue2.10 – In recent years, the UK has lost ground internationally as a valued country site for undertaking clinical investigations of medical technology and later-phase clinical trials for drugs. In particular, trial start-up times, recruitment, reliability and cost have impacted significantly on the overall cost-effectiveness of the UK as a site for clinical research. The Government, through the Department of Health and the NIHR, and working closely with industry, is putting in place a range of measures specifically to address these issues. Nevertheless, the Government believes that more can be done.

OLS solution – A package of measures:

The Government will reinforce the need for greater emphasis on research (a) and clinical trials in the next NHS Operating Framework, building on the existing commitment to include numbers of patients in clinical research in the metrics which Trusts report in their Quality Accounts;

The Government will support the NHS in creating a national framework (b) for professional local management of health research, transitioning R&D Departments to become NIHR Research Support Services Departments adopting standard operating procedures and a shared risk-based approach in order to create a step-change in speed and reliability for commercial and non-commercial trials in the NHS;

To underline the strategic importance of health research to the NHS, the (c) Government will clarify the duty on SHAs to promote innovation to highlight their role in promoting R&D across healthcare organisations; and

16


To ensure the UK fully exploits its position as a world leader in health (d) informatics, the Government will build on the momentum generated by NHS Connecting for Health’s Research Capability Programme and its equivalents in the Devolved Administrations by:

Working with the major stakeholders to implement and resource the (i) Strategic Framework agreed by the OSCHR E-Health Records Research Board; and

Ensuring the development of a clear implementation plan by the end (ii) of 2009, with business cases and joint piloting with industry.

17


18

Chapter 3


The future of a flourishing UK life sciences industry lies in integration 3.1 and collaboration, across industry, academia and the NHS. It is vital to its continued success that the supply of high-calibre skilled employees is maintained.

A world-class research base is the foundation of any high-tech industry. The 3.2 UK’s Higher Education (HE) system is recognised worldwide for its excellence in teaching and research, and many life sciences companies are built on the exploitation of this cutting-edge research.

The number of students studying chemistry, biology and maths at ‘A’ level or 3.3 equivalent has risen (by 11.6%, 8.6% and 20.1% respectively) over the last five years. The UK’s HE system is a national asset. Applications to study Science Technology Engineering and Maths (STEM) subjects at HE level are increasing. As centres of research excellence, HE Institutions (HEIs), in partnership with industry, are key drivers of economic growth and lay the foundations for innovation. This excellence has been, and continues to be, a strong pull to attract and retain life science business interests in the UK. However, in some areas, we need to do more to ensure that UK graduates leave with the relevant core skills and disciplines to equip them to enter the life sciences workforce.

The 3.4 New Industry, New Jobs strategy paper published in April 2009 outlined the Government’s intent to take action, where appropriate, to address the skills and knowledge gaps that constrain UK-based businesses’ ability to compete globally. It acknowledged the key role for life sciences in the future growth of the UK economy. Later this year, Government will publish a Higher Education Framework, that will set out how the activist approach of New Industry, New Jobs will be applied in the HE sector. It will be a comprehensive overview of the future role of HE, ensuring that Government supports the HE sector and employers, including those in life sciences, in working together to address the skills needs of the industry.

Issue3.5 – The Association of the British Pharmaceutical Industry (ABPI) reported, in its 2008 report Skills Needs for Biomedical Research7, that employers are concerned that the level of flexibility and variability in the content of undergraduate bioscience courses is affecting the number of graduates gaining sufficient practical and high-level maths skills that can be applied within a scientific context. Therefore industry requires more UK life sciences graduates with these skills. This view has also been articulated by the expert groups

7 http://abpi.org.uk/publications/pdfs/2008-10STEMSkillsReviewReportFINALamended2.pdf

19

which have come together within the newly-formed Society of Biology, as well as the HE Academy for Bioscience, Heads of University Biological Sciences, and the Council for Industry and Higher Education.

OLS solution – From 2010, the Society of Biology will begin to accredit undergraduate bioscience degrees to help ensure that graduates leave with the core mathematical and practical skills and competencies required by employers.

Issue3.6 – Industry feels that there is not a co-ordinated mechanism for it to discuss its needs with HEIs and funders in a coherent and collective way, and to work with them to bring about the change needed to address the skill gaps that it has identified in undergraduate bioscience degrees.

OLS solution – The Government will, in partnership with the HE sector and industry, establish an industry and HE forum, based on the successful high-level STEM strategy group model. This will, for example, enable life sciences employers to agree with universities what specialised course content they need to address critical skills gaps and to prioritise actions to be taken.

In the event that a need is identified for Government action to increase volumes in specific areas, the Government will discuss with the Higher Education Funding Council for England (HEFCE) the use of strategic funding to incentivise the development of new provision, or new types of provision.

The first two tasks of this forum will be to assess the curriculum for clinical pharmacology in medical and pharmacy degrees and higher medical training, and evaluate the impact of the significant public and industry funding in addressing the in vivo sciences (pharmacology, pathology, toxicology and physiology) skills gaps, and agree actions that will address these gaps by November 2009.

Issue3.7 – In order to build a successful small and medium life sciences company, business and leadership skills are as vital as the innovative science that led to its formation. However life sciences companies feel that they do not have the resources to invest in developing management and leadership skills across their organisations.

OLS solution – A new business and leadership programme for life sciences SMEs has been developed in collaboration with industry and will be launched by the end of 2009. Over the summer, the Government will work with education funders and industry to agree how the programme will be funded.

Issue3.8 – The Research Assessment Exercise (RAE) rewarded HEIs for excellent research but did not take explicit account of the impact that research had on UK businesses or the nation as a whole. There have been concerns that this

20


acted as a barrier to translating research into actual commercial applications or industrial collaboration.

OLS solution – The new Research Excellence Framework (REF), currently under development, will explicitly assess the economic and social impact of research. It will take into account, for example, the translation of research into new products and services, collaborative working between academia and business, and between academia and public services and policy makers. For life sciences, the new Framework will, for example, reward HEIs whose broad range of clinical academics have developed, adopted and diffused innovative research into clinical practice. The new Framework will be announced in 2010.

Issue3.9 – The UK life sciences industry can only retain its position as a global leader if there is deep and sustained collaboration across industry, academia and the NHS.


In a number of areas in the UK (such as the North West, Scotland and the (a) greater South East), industry, Higher Education, the NHS, and medical research charities are already working closely together. They are building on existing architecture, such as Academic Health Science Centres, with the aim of achieving the same international recognition as overseas clusters such as Boston, USA. By November 2009, the Government will complete further work on how the formation of a UK Life Sciences Super Cluster can best be supported. This will build on the UK’s clinical and academic excellence. It will focus on areas where there is a willingness on the part of industry, Higher Education and the NHS to work together to leverage collaborative effort to deliver life sciences innovation. Government will also consider how the Super Cluster can be included as part of the UK Trade and Investment life sciences marketing initiatives.

OSCHR Partners, working with OSCHR, will lead work to develop and (b) implement, by early 2010, a single coherent strategy across all relevant agencies (the Technology Strategy Board, Knowledge Transfer Networks, the RDAs, the Research Councils and the Health Departments). A single strategy will enable coherent communication of the opportunities available to industry for collaboration, funding sources and infrastructure support. OSCHR Partners, working with OSCHR, will offer clear leadership for this work, bringing to bear deep knowledge of the Higher Education sector and of industry.

In addition, the Government will ensure that continued funding from the (c) National Institute for Health Research for Biomedical Research Centres, Biomedical Research Units and Clinical Research Facilities will be partly contingent on demonstrable working with industry.

21


The Government will explore which mechanisms are most effective (d) in encouraging students to study those subjects that meet employer demand and national priorities. For example, it will work with HEIs and life sciences employers to offer better information, advice and guidance about course content, graduate destinations and how universities link up with employers (e.g. through work placements). This is one of the ways that students will be able to access the opportunities the life sciences industry offers them.

Issue3.10 – The provision of high quality-care requires clinicians to be familiar with the relevant practices in clinical pharmacology and pathology. This is important to enable them to evaluate and prescribe innovative medicines.

OLS solution – In early 2010, the Medical Research Council will launch a £3.5 million flagship programme in clinical pharmacology and pathology, enhancing professional skills and driving collaboration with industry.

22


Chapter 4

The number one need for small life sciences companies is funding, to 4.1 secure the future drug development pipeline, UK-generated IP and associated jobs. The Review and Refresh of Bioscience 2015 report8 also described the increasingly symbiotic relationship between small and large companies.

With a global life sciences industry, it is vital that the UK offers an environment 4.2 in which large companies are incentivised to invest in and contribute to the future of smaller companies. Long-term investment decisions on where to locate activity are made on a global basis and take into account a range of factors.

The UK incentivises innovative activity through the tax system. In particular, 4.3 the research and development (R&D) tax credit encourages the creation of intellectual property (IP), whilst the corporate intangible assets regime encourages acquiring and holding IP assets. The R&D tax credit provides support of over £800m per year to small and large companies, and the regime for corporate intangible assets, introduced in 2002, allows companies additional relief against the assets such as IP. The Government continues to keep these aspects of the tax system under review, in line with its objectives of competitiveness, encouraging investment, promoting innovation and ensuring fairness.

Issue4.4 – Life sciences small and medium enterprises (SMEs) are facing increasing difficulty in securing venture capital (VC) investment, threatening the future of highly innovative and world-leading R&D.

OLS solution – On 29 June 2009, the Government announced the creation of a UK Innovation Investment Fund to invest in technology-based businesses with high-growth potential. The new Fund will focus on investing in growing small businesses, start-ups and spin-outs in four high-tech sectors, including the life sciences. The Government will invest £150 million alongside private sector investment on an equal basis, with the aim of leveraging enough private investment to build a £1 billion, 10-year VC Fund.

8 http://www.berr.gov.uk/files/file49805.pdf

23

Issue4.5 – The UK is well placed to attract globally mobile life sciences investment as a result of its excellent science base, skilled workforce, and business-friendly environment. But global competition to attract and retain this investment is increasing, with skills and infrastructure improving in other countries. Policies are also being introduced overseas to attract innovative activity, including through low corporate tax rates and enhanced reliefs, and that attract IP assets through special tax regimes on IP income, termed “patent boxes”.

OLS solution – The Government already incentivises innovative activity through the tax system. Budget 2009 announced that the Government would consider evidence for further changes to the way the tax system encourages innovative activity, to ensure the ongoing competitiveness of the UK.

The Government is committed to ensuring the UK remains an attractive location for investment in innovative activity. The work is examining the role of business tax in encouraging investment in innovation, and the impact on jobs and productivity growth in the UK. It is also considering how the UK tax system compares to other regimes internationally, and the role that taxes play in decisions on where to locate innovative investment, including the location of dedicated R&D and manufacturing centres, and patent development. This assessment will allow the Government to ensure that the tax system provides the appropriate conditions for investment in innovation and to drive productivity, growth and jobs.

Investment in innovation occurs across a diverse range of activities and sectors. Since the Budget announcement, HM Treasury, along with the Department for Business, Innovation and Skills, has met with businesses across a wide range of sectors, including the life sciences, to gather evidence on innovation and the role of taxation.

Businesses have highlighted that, across many innovative activities, the strength of the science and skills base is the primary driver of investment decisions. The UK is strong in these and other key factors, such as the regulatory and legal environment. Taxation can also play an important role in investment decisions and a competitive rate of corporation tax, as well as a regime that provides certainty and minimizes complexity for all businesses is seen as increasingly important by businesses.

The work is considering whether there is scope to improve or enhance the way the tax system encourages innovation. Many businesses have pointed to the attractiveness of countries offering low corporation tax rates, particularly where they are able to match the UK in providing a skilled workforce and business-friendly environment. Therefore the benefits of introducing or enhancing specific tax reliefs and incentives will be set against the benefits of further reductions in the rate of corporation tax, which the Government continues to keep under review.

24


These discussions are focusing on the entire innovation chain: the creation of value, including research and development; securing that value, such as through patents and other intellectual property; and unlocking value, including through production or licensing. This chain of activity is global and can involve a range of actors around the world. The work is assessing the strength of links between these activities and the balance between tax and non-tax factors in driving investment decisions.

There is strong support among all businesses for the current R&D tax credits, particularly among SMEs where the credit is seen as critical in supporting cash flow. There is evidence to support the effectiveness of such incentives in increasing the level of R&D and the work is seeking to ensure the impact of the credits is maximised.

Some businesses have highlighted tax regimes introduced in some EU Member States in recent years that provide a preferential rate of tax on income earned from intellectual property, for example “patent boxes”. HM Treasury is exploring the extent to which such schemes could encourage intellectual property to be located in the UK and the impact this could have by way of additional and productive investment in the UK.

In evaluating proposals for change, evidence on the long-term impact on productivity and employment will be crucial. The potential impact on tax receipts in the short- and long-term will also be a key factor in the assessment. This will draw on analysis of the full costs of introducing any changes, taking into account any current pressures on the tax base. Any potential changes will also be considered alongside the Government’s wider approach to business taxation, including providing certainty and stability and minimizing complexity, as well as meeting international commitments.

The evidence will be assessed over the summer, drawing on the expertise of the Business-Government Forum on Tax and Globalisation, as well as through further discussions with businesses and the wider innovation community. HM Treasury will set out its assessment and proposed approach before the 2009 Pre-Budget Report. If proposals can be developed that meet the considerations set out above, Government would consult widely with businesses before making any changes.

Issue4.6 – Consortium relief allows a company owned by a consortium to surrender a portion of its current year tax losses to the members of the consortium to offset against their taxable profits. Life science companies have suggested that the investor structure in many small life sciences companies can preclude those investors from benefiting from consortium relief and that changes to this feature of Group Relief would have the potential to incentivise investment in SMEs by large companies.

OLS solution – As with all areas of tax, the Treasury keeps this under review, and will consider the case for any changes.

Issue4.7 – There is the opportunity for the NHS to deliver a better service to patients through the procurement of innovative products from life sciences companies.


The National Innovation Centre (NIC) held five NHS/industry “Wouldn’t It (a) Be Great If…. (WIBGI)” workshops at the NHS Innovation Expo in June 2009. The workshops focussed on cardiac care, urology, paediatrics, ambulance services, and regenerative medicine, which generated a short-list of opportunities for the NHS. Beginning in September 2009, the NIC, working jointly with the Strategic Health Authorities (SHAs), the Technology Strategy Board, and Knowledge Transfer Networks, will launch a series of Small Business Research Initiative (SBRI) competitions to engage industry and the NHS. Over the next 12 months, the NIC will support a rolling series of coordinated SBRI initiatives that start with NHS clinicians defining their clinical needs, and end with industry engaging with the NHS to develop compelling solutions; and

The new SHA Delivery Group will lead work to develop an NHS SBRI (b) prospectus that will set out future needs in key healthcare areas. The Group will also hold an annual conference to better understand the potential of industry to provide solutions. Further details and timetables will be set out by November 2009.

Issue4.8 – To capitalise fully on our leading global position in regenerative medicine, there are a number of challenges that need to be overcome, particularly access to funding and supply of bespoke infrastructure.

OLS solution – In September 2009, to support this growing and strategically important industry, the Technology Strategy Board will launch an £18 million “RegenMed” programme of investment to support key areas of commercial R&D and the development of R&D partnerships. The programme will be developed in partnership with the Medical Research Council, the Engineering and Physical Sciences Research Council, and the Biotechnology and Biological Sciences Research Council who will provide additional funding of at least £3.5 million. Programme development will be guided by a high-level industrially-focussed group comprising industry and academic experts.

The programme will have three strands:

Regenerative medicine product development and validation;(i)

Grand challenges in underpinning tools and technologies; and(ii)

Understanding value systems and business models necessary for the (iii) delivery of regenerative medicines.

The Technology Strategy Board has also committed to increase its expertise in the life sciences.

25


26

Chapter 5

Marketing UK life sciences

The actions listed in this Blueprint have the potential to transform the UK 5.1 life sciences industry. This will only be realised fully through effective global marketing. For the first time ever, the UK has a single marketing strategy for the life sciences industry, in itself a transformational change. The industry-led UK Life Sciences Marketing Strategy Board will take full advantage of this by accelerating marketing activity over the next 6 months.

Issue5.2 – Increased effective marketing is needed to ensure international companies are aware of the UK’s strengths and the new opportunities presented by the actions in this Blueprint.


UK Trade and Investment (UKTI) will coordinate a series of high-level events (a) overseas, beginning with a summer 2009 US tour by a senior UK delegation to engage with key US-based life sciences companies and increase their investment in the UK; and

By March 2011, UKTI will invest £1 million from the Strategic Investment (b) Fund to further promote the UK and NHS brands at flagship life sciences events in the UK and overseas. For example, through supporting UK companies attendance at AdvaMed9 in Washington in October 2009, and at Medica10 in Düsseldorf in November 2009. In addition, UKTI will hold a new high-level technology partnering event later in 2010 that will bring life sciences decision-makers to the UK.

Issue5.3 – The industry-led UK Life Sciences Marketing Strategy Board is committed to bringing the life sciences industry across the UK together with a single voice when marketing UK life sciences internationally.

OLS solution – The OLS and UKTI will hold a series of roadshows throughout the English regions and Devolved Administrations, beginning in September. These roadshows will bring together businesses with other key regional stakeholders to:

9 AdvaMed is the premier high level MedTech conference in the US.10 Medica is the world’s largest MedTech trade fair with over 4000 exhibitors in 2008.

27

Discuss the Blueprint commitments and next steps to implement them; (i) and

Help ensure the UK life sciences industry speaks with one consistent (ii) voice in its global marketing activities.

Issue5.4 – Actions such as the creation of a UK Innovation Investment Fund make the UK an even more favourable environment for investors, including multi-national corporate venture funds who have not frequently invested in the UK.

OLS solution – From summer 2009, specialists will meet with corporate venture funds to build upon the strong foundations provided by the UK Innovation Investment Fund and attract additional investment in the UK.

Issue5.5 – Chapter 3 of this Blueprint includes actions to enhance the UK’s regional centres of excellence and transform them into a UK Life Sciences Super Cluster. These UK concentrations of excellence do not currently have the international profile of key international equivalents such as the Boston life sciences cluster.

OLS solution – The UK will form strategic alliances with key US life sciences clusters in line with proposals for a UK Life Sciences Super Cluster (see Chapter 3). This will be piloted by collaboration between Boston and the golden triangle (London, Cambridge and Oxford), beginning with the signing of a Memorandum of Understanding in October 2009.

28

Next steps

The actions set out in this Life Sciences Blueprint have the potential to transform the environment for life sciences companies in the UK, ensuring the industry realises its potential as a major driver of economic growth and of improved health and wellbeing.

The establishment of the Office for Life Sciences has initiated a new way of working between Government and the life sciences industry. It will now be crucial to implement the commitments in this Blueprint, developing detailed delivery plans for each action. A further document, to be published in autumn 2009, will set out these plans.

A Blueprint communications strategy will be rolled out to key audiences in the UK, and globally through UK Trade and Investment.

The Government is committed to continuing the effective collaboration between Government departments and industry which has been a feature of the first phase of Office for Life Sciences’ work, and to closer involvement of the NHS, the Higher Education sector and other partners.

30

Ann

ex

Life

Sci

ence

s A

ctio

n P

lan

This

tab

le s

ets

out

the

Gov

ernm

ent’s

key

new

pol

icy

com

mitm

ents

, des

crib

es w

hat

is b

eing

del

iver

ed, a

nd b

y w

hen,

as

wel

l as

indi

catin

g w

ho is

res

pons

ible

.

Po

licy

Mea

sure

By

wh

en?

Wh

o?

Bu

dg

et

TH

E N

HS

AS

AN

INN

OV

AT

ION

CH

AM

PIO

N

The

Gov

ernm

ent,

with

NIC

E, w

ill in

trod

uce

an “

Inno

vatio

n P

ass”

. Thi

s w

ill b

e a

thre

e-ye

ar in

itiat

ive

for

sele

cted

med

icin

es, w

hich

will

be

fund

ed f

or t

ime-

limite

d us

e ac

ross

the

NH

S, f

rom

a n

ew r

ing-

fenc

ed b

udge

t, w

ithou

t go

ing

thro

ugh

a N

ICE

app

rais

al. N

ICE

will

pla

y a

key

role

in d

evel

opin

g an

d ap

plyi

ng e

ligib

ility

crit

eria

for

the

Pas

s. T

his

will

giv

e ea

rlier

acc

ess

to in

nova

tive

drug

s fo

r pa

tient

s w

ith t

he g

reat

est

need

. The

Pas

s w

ill b

e pi

lote

d w

ith a

bud

get

of £

25 m

illio

n in

201

0/20

11. T

he

pilo

t w

ill b

e de

velo

ped

with

inpu

t fr

om in

dust

ry, N

ICE

and

the

NH

S a

nd w

ill b

e th

e su

bjec

t of

a

cons

ulta

tion.

Fun

ding

for

fut

ure

year

s w

ill a

lso

be d

iscu

ssed

thr

ough

the

con

sulta

tion

and

will

the

n be

det

erm

ined

in t

he c

onte

xt o

f th

e ne

xt s

pend

ing

revi

ew.

To b

e pi

lote

d in

20

10/2

011,

with

a

cons

ulta

tion

on t

he p

ilot

by

Nov

embe

r 20

09

DH

/NIC

E£2

5 m

illio

n

Com

pani

es w

ith t

echn

olog

ies

bein

g ap

prai

sed

by N

ICE

will

be

able

to

atte

nd N

ICE

app

rais

al

com

mitt

ee m

eetin

gs t

o re

spon

d to

any

que

stio

ns f

rom

the

com

mitt

ee, a

nd w

ill h

ave

an o

ppor

tuni

ty

to c

omm

ent

on m

atte

rs o

f fa

ctua

l acc

urac

y. A

t th

e en

d of

a N

ICE

app

rais

al, m

anuf

actu

rers

will

be

prov

ided

with

the

opp

ortu

nity

to

have

a d

ebrie

fing

mee

ting

with

NIC

E, a

nd E

vide

nce

Rev

iew

Gro

ups

will

be

aske

d to

att

end

scop

ing

mee

tings

for

NIC

E S

ingl

e Te

chno

logy

App

rais

als.

Agr

eed.

For

im

plem

enta

tion

DH

/NIC

EN

/A

Sir

Ian

Ken

nedy

is c

ondu

ctin

g a

stud

y to

iden

tify

the

aspe

cts

of v

alue

and

inno

vatio

n w

hich

NIC

E

shou

ld t

ake

into

acc

ount

in it

s w

ork.

His

rep

ort

will

be

publ

ishe

d on

22

July

200

9. N

ICE

will

con

duct

a

one-

mon

th p

ublic

con

sulta

tion

on it

s re

spon

se t

o th

e K

enne

dy r

epor

t in

Sep

tem

ber

2009

, and

th

is is

sue

will

con

tinue

to

be a

n im

port

ant

part

of

the

OLS

wor

k pr

ogra

mm

e in

to t

he a

utum

n. F

rom

N

ovem

ber

2009

, NIC

E w

ill a

lso

impl

emen

t im

prov

emen

ts in

the

way

in w

hich

it e

xpla

ins

the

impa

ct

of s

peci

fic f

acto

rs in

its

deci

sion

-mak

ing.

Con

sulta

tion

to b

e he

ld in

S

epte

mbe

r 20

09

NIC

EN

/A

31

Po

licy

Mea

sure

By

wh

en?

Wh

o?

Bu

dg

et

A p

acka

ge o

f m

easu

res

to a

ddre

ss t

he u

ptak

e is

sue:

(a)

The

Gov

ernm

ent

will

est

ablis

h an

SH

A D

eliv

ery

Gro

up w

hich

will

be

chai

red

by a

n S

HA

chi

ef

exec

utiv

e. T

he D

eliv

ery

Gro

up w

ill w

ork

to:

(i)

In

crea

se t

he u

ptak

e of

cos

t ef

fect

ive

drug

s;

(ii

) Im

prov

e th

e st

rate

gic

rela

tions

hip

betw

een

the

NH

S a

nd in

dust

ry s

o th

at b

oth

can

wor

k to

geth

er b

ette

r in

a m

ore

busi

ness

-to-

busi

ness

man

ner;

(ii

i) Im

prov

e th

e co

mpe

titiv

enes

s of

the

UK

as

a si

te f

or c

linic

al r

esea

rch;

and

(iv

) P

ut in

pla

ce e

quiv

alen

t N

HS

-led

arra

ngem

ents

to

supp

ort

the

early

and

sys

tem

atic

upt

ake

of in

nova

tions

in m

edic

al t

echn

olog

ies

whi

ch p

rovi

de v

alue

to

the

NH

S.

(b)

The

Gov

ernm

ent

will

con

tinue

wor

k on

exi

stin

g an

d pr

opos

ed m

etric

s to

pro

vide

an

auth

orita

tive

com

paris

on o

f th

e up

take

of

cost

-eff

ectiv

e m

edic

ines

bot

h w

ithin

the

NH

S a

nd o

n an

inte

rnat

iona

l ba

sis.

It w

ill a

lso

deve

lop,

by

autu

mn

2010

, a p

ilot

set

of m

etric

s ag

ains

t w

hich

NH

S o

rgan

isat

ions

ca

n as

sess

the

mse

lves

in r

elat

ion

to t

he u

ptak

e of

cos

t-ef

fect

ive

inno

vativ

e te

chno

logi

es.

(c)

The

Gov

ernm

ent

will

ens

ure

that

at

leas

t tw

o of

the

new

Com

mer

cial

Sup

port

Uni

ts (C

SU

s)

to b

e se

t up

, und

er t

he n

ew N

HS

Com

mer

cial

Ope

ratin

g M

odel

, will

dev

elop

and

tes

t re

gion

al

appr

oach

es t

o su

ppor

t in

nova

tions

fro

m t

he m

edic

al t

echn

olog

y se

ctor

, thr

ough

eng

agem

ent

with

NH

S a

t an

ear

ly s

tage

of

prod

uct

deve

lopm

ent.

(d)

The

Gov

ernm

ent

will

wor

k w

ith t

he N

HS

to

build

inno

vatio

n in

to t

he e

duca

tion

com

mis

sion

ing

syst

em a

nd b

y au

tum

n 20

09 w

ill p

rovi

de g

uida

nce

on w

hat

SH

A c

omm

issi

oner

s ca

n do

to

achi

eve

this

.

By

Nov

embe

r 20

09D

H/N

HS

N/A

32


Po

licy

Mea

sure

By

wh

en?

Wh

o?

Bu

dg

et

The

NH

S C

hief

Exe

cutiv

e is

put

ting

in p

lace

a p

acka

ge o

f m

easu

res

to b

ring

prio

rity

and

pace

to

the

QIP

P a

gend

a:

(a)

The

NH

S C

hief

Exe

cutiv

e w

ill t

ake

pers

onal

res

pons

ibili

ty f

or t

he N

HS

’ pro

gram

me

of a

ctio

n to

dr

ive

grea

ter

qual

ity, i

nnov

atio

n, p

rodu

ctiv

ity, a

nd p

reve

ntio

n (Q

IPP

);

(b)

The

NH

S M

anag

emen

t B

oard

will

del

egat

e ov

ersi

ght

of t

he d

ay-t

o-da

y ru

nnin

g of

NH

S

oper

atio

nal i

ssue

s to

a n

ew N

HS

Ope

ratio

ns B

oard

, lea

ving

the

Man

agem

ent

Boa

rd t

o fo

cus

excl

usiv

ely

on t

he Q

IPP

age

nda;

(c)

Ther

e w

ill b

e a

maj

or e

ngag

emen

t pr

oces

s th

roug

hout

the

hea

lthca

re s

yste

m, w

ith t

he B

oard

of

eve

ry N

HS

org

anis

atio

n ex

pect

ed t

o en

gage

with

sta

ff, i

ndus

try

– in

clud

ing

the

life

scie

nces

in

dust

ry –

and

oth

er p

artn

ers

on h

ow in

nova

tion

can

best

be

harn

esse

d to

impr

ove

qual

ity a

nd

redu

ce c

osts

at

all l

evel

s of

the

sys

tem

;

(d)

The

idea

s ge

nera

ted

by t

his

proc

ess

will

info

rm t

he N

HS

Ope

ratin

g Fr

amew

ork

for

2010

-201

1;

(e)

Sim

ulta

neou

sly

the

NH

S C

hief

Exe

cutiv

e w

ill a

lso

lead

a r

evie

w o

f th

e sy

stem

leve

rs a

nd

ince

ntiv

es, s

uch

as P

aym

ent

By

Res

ults

(PB

R) ,

and

how

the

y m

ight

be

bett

er d

eplo

yed

to

acce

lera

te Q

IPP

; and

(f)

The

NH

S L

eade

rshi

p C

ounc

il w

ill t

ake

step

s to

inte

nsify

the

sha

ring

of s

kills

and

exp

erie

nce

with

in

dust

ry le

ader

s to

sup

port

mor

e st

rate

gic

colla

bora

tion

to d

rive

inno

vatio

n an

d br

ing

bene

fits

to

patie

nts.

Agr

eed.

Im

plem

enta

tion

star

ting

imm

edia

tely

DH

N/A

33

Life Sciences Action Plan

Po

licy

Mea

sure

By

wh

en?

Wh

o?

Bu

dg

et

A p

acka

ge o

f m

easu

res

to im

prov

e th

e U

K e

nviro

nmen

t fo

r cl

inic

al t

rials

:

(a)

The

Gov

ernm

ent

will

rei

nfor

ce t

he n

eed

for

grea

ter

emph

asis

on

rese

arch

and

clin

ical

tria

ls in

th

e ne

xt N

HS

Ope

ratin

g Fr

amew

ork,

bui

ldin

g on

the

exi

stin

g co

mm

itmen

t to

incl

ude

num

bers

of

patie

nts

in c

linic

al r

esea

rch

in t

he m

etric

s w

hich

Tru

sts

repo

rt in

the

ir Q

ualit

y A

ccou

nts;

(b)

The

Gov

ernm

ent

will

sup

port

the

NH

S in

cre

atin

g a

natio

nal f

ram

ewor

k fo

r pr

ofes

sion

al lo

cal

man

agem

ent

of h

ealth

res

earc

h, t

rans

ition

ing

R&

D D

epar

tmen

ts t

o be

com

e N

IHR

Res

earc

h S

uppo

rt S

ervi

ces

Dep

artm

ents

ado

ptin

g st

anda

rd o

pera

ting

proc

edur

es a

nd a

sha

red

risk-

base

d ap

proa

ch in

ord

er t

o cr

eate

a s

tep-

chan

ge in

spe

ed a

nd r

elia

bilit

y fo

r co

mm

erci

al a

nd n

on-

com

mer

cial

tria

ls in

the

NH

S;

(c)

To u

nder

line

the

stra

tegi

c im

port

ance

of

heal

th r

esea

rch

to t

he N

HS

, the

Gov

ernm

ent

will

cl

arify

the

dut

y on

SH

As

to p

rom

ote

inno

vatio

n to

hig

hlig

ht t

heir

role

in p

rom

otin

g R

&D

acr

oss

heal

thca

re o

rgan

isat

ions

; and

(d)

To e

nsur

e th

e U

K f

ully

exp

loits

its

pote

ntia

l to

be a

wor

ld le

ader

in h

ealth

info

rmat

ics,

the

G

over

nmen

t w

ill b

uild

on

the

mom

entu

m g

ener

ated

by

NH

S C

onne

ctin

g fo

r H

ealth

’s R

esea

rch

Cap

abili

ty P

rogr

amm

e an

d its

equ

ival

ents

in t

he D

evol

ved

Adm

inis

trat

ions

by:

(i)

W

orki

ng w

ith t

he m

ajor

sta

keho

lder

s to

impl

emen

t an

d re

sour

ce t

he S

trat

egic

Fra

mew

ork

agre

ed b

y th

e O

SC

HR

E-H

ealth

Rec

ords

Res

earc

h B

oard

; and

(ii

) E

nsur

ing

the

deve

lopm

ent

of a

cle

ar im

plem

enta

tion

plan

by

the

end

of 2

009,

with

bus

ines

s ca

ses

and

join

t pi

lotin

g w

ith in

dust

ry.

(a) A

utum

n 20

09

(b) B

y A

pril

2010

(c

) Alre

ady

unde

rway

(d) B

y th

e en

d of

200

9

DH

N

/A

BU

ILD

ING

A M

OR

E IN

TE

GR

AT

ED

LIF

E S

CIE

NC

ES

IND

US

TR

Y

The

Soc

iety

of

Bio

logy

will

beg

in t

o ac

cred

it un

derg

radu

ate

bios

cien

ce d

egre

es t

o he

lp e

nsur

e th

at

grad

uate

s le

ave

with

the

cor

e sk

ills

and

com

pete

ncie

s re

quire

d by

em

ploy

ers.

From

201

0S

ocie

ty o

f B

iolo

gy

N/A

34


Po

licy

Mea

sure

By

wh

en?

Wh

o?

Bu

dg

et

The

Gov

ernm

ent

will

, in

part

ners

hip

with

the

HE

sec

tor

and

indu

stry

, est

ablis

h an

indu

stry

and

HE

fo

rum

, bas

ed o

n th

e su

cces

sful

hig

h-le

vel S

TEM

str

ateg

y gr

oup

mod

el. T

his

will

, for

exa

mpl

e, e

nabl

e lif

e sc

ienc

es e

mpl

oyer

s to

agr

ee w

ith u

nive

rsiti

es w

hat

spec

ialis

ed c

ours

e co

nten

t th

ey n

eed

to

addr

ess

criti

cal s

kills

gap

s an

d to

prio

ritis

e ac

tions

to

be t

aken

.

In t

he e

vent

tha

t a

need

is id

entifi

ed f

or G

over

nmen

t ac

tion

to in

crea

se v

olum

es in

spe

cific

ar

eas,

the

Gov

ernm

ent

will

dis

cuss

with

HE

FCE

the

use

of

stra

tegi

c fu

ndin

g to

ince

ntiv

ise

the

deve

lopm

ent

of n

ew p

rovi

sion

, or

new

typ

es o

f pr

ovis

ion.

The

first

tw

o ta

sks

of t

his

foru

m w

ill b

e to

ass

ess

the

curr

icul

um f

or c

linic

al p

harm

acol

ogy

in m

edic

al

degr

ees

and

high

er m

edic

al t

rain

ing,

and

ass

ess

the

impa

ct o

f th

e si

gnifi

cant

pub

lic a

nd in

dust

ry

fund

ing

in a

ddre

ssin

g th

e in

viv

o sc

ienc

es (p

harm

acol

ogy,

pat

holo

gy, t

oxic

olog

y an

d ph

ysio

logy

) ski

lls

gap

and

agre

e ac

tions

.

By

Nov

embe

r 20

09In

dust

ry/

Hig

her

Edu

catio

n se

ctor

/BIS

N/A

A n

ew b

usin

ess

and

lead

ersh

ip p

rogr

amm

e fo

r lif

e sc

ienc

es S

ME

s ha

s be

en d

evel

oped

in

colla

bora

tion

with

indu

stry

. Ove

r th

e su

mm

er, t

he G

over

nmen

t w

ill w

ork

with

edu

catio

n fu

nder

s an

d in

dust

ry t

o ag

ree

how

the

pro

gram

me

will

be

fund

ed.

To b

e la

unch

ed

by t

he e

nd o

f 20

09

BIS

TBC

The

new

Res

earc

h E

xcel

lenc

e Fr

amew

ork,

cur

rent

ly u

nder

dev

elop

men

t, w

ill e

xplic

itly

asse

ss t

he

econ

omic

and

soc

ial i

mpa

ct o

f re

sear

ch. I

t w

ill t

ake

into

acc

ount

, for

exa

mpl

e, t

he t

rans

latio

n of

re

sear

ch in

to n

ew p

rodu

cts

and

serv

ices

, col

labo

rativ

e w

orki

ng b

etw

een

acad

emia

and

bus

ines

s,

and

betw

een

acad

emia

and

pub

lic s

ervi

ces

and

polic

y m

aker

s. F

or li

fe s

cien

ces,

the

new

Fra

mew

ork

will

, for

exa

mpl

e, r

ewar

d H

EIs

who

se b

road

ran

ge o

f cl

inic

al a

cade

mic

s ha

ve d

evel

oped

, ado

pted

an

d di

ffus

ed in

nova

tive

rese

arch

into

clin

ical

pra

ctic

e.

The

new

Fr

amew

ork

will

be

ann

ounc

ed in

S

prin

g 20

10

BIS

N/A

35


Po

licy

Mea

sure

By

wh

en?

Wh

o?

Bu

dg

et

A p

acka

ge o

f m

easu

res

to d

eepe

n in

dust

ry, N

HS

and

Hig

her

Edu

catio

n co

llabo

ratio

n:

(a)

In a

num

ber

of a

reas

in t

he U

K (s

uch

as t

he N

orth

Wes

t, S

cotla

nd a

nd t

he g

reat

er S

outh

Eas

t),

indu

stry

, Hig

her

Edu

catio

n, t

he N

HS

, and

med

ical

res

earc

h ch

ariti

es a

re a

lread

y w

orki

ng c

lose

ly

toge

ther

. The

y ar

e bu

ildin

g on

exi

stin

g ar

chite

ctur

e, s

uch

as A

cade

mic

Hea

lth S

cien

ce C

entr

es,

with

the

aim

of

achi

evin

g th

e sa

me

inte

rnat

iona

l rec

ogni

tion

as o

vers

eas

clus

ters

suc

h as

B

osto

n, U

SA

. By

Nov

embe

r 20

09, t

he G

over

nmen

t w

ill c

ompl

ete

furt

her

wor

k on

how

the

fo

rmat

ion

of a

UK

Life

Sci

ence

s S

uper

Clu

ster

can

bes

t be

sup

port

ed. T

his

will

bui

ld o

n th

e U

K’s

cl

inic

al a

nd a

cade

mic

exc

elle

nce.

It w

ill f

ocus

on

area

s w

here

the

re is

a w

illin

gnes

s on

the

par

t of

indu

stry

, Hig

her

Edu

catio

n an

d th

e N

HS

to

wor

k to

geth

er t

o le

vera

ge c

olla

bora

tive

effo

rt t

o de

liver

life

sci

ence

s in

nova

tion.

Gov

ernm

ent

will

als

o co

nsid

er h

ow t

he S

uper

Clu

ster

can

be

incl

uded

as

part

of

the

UK

Tra

de a

nd In

vest

men

t lif

e sc

ienc

es m

arke

ting

initi

ativ

es.

(b)

OS

CH

R P

artn

ers,

wor

king

with

OS

CH

R, w

ill le

ad w

ork

to d

evel

op a

nd im

plem

ent

a si

ngle

co

here

nt s

trat

egy

acro

ss a

ll re

leva

nt a

genc

ies

(the

Tec

hnol

ogy

Str

ateg

y B

oard

, Kno

wle

dge

Tran

sfer

Net

wor

ks, t

he R

DA

s, t

he R

esea

rch

Cou

ncils

and

the

Hea

lth D

epar

tmen

ts).

A s

ingl

e st

rate

gy w

ill e

nabl

e co

here

nt c

omm

unic

atio

n of

the

opp

ortu

nitie

s av

aila

ble

to in

dust

ry f

or

colla

bora

tion,

fun

ding

sou

rces

and

infr

astr

uctu

re s

uppo

rt. O

SC

HR

Par

tner

s, w

orki

ng w

ith

OS

CH

R, w

ill o

ffer

cle

ar le

ader

ship

for

thi

s w

ork,

brin

ging

to

bear

dee

p kn

owle

dge

of t

he H

ighe

r E

duca

tion

sect

or a

nd o

f in

dust

ry.

(c)

In a

dditi

on, t

he G

over

nmen

t w

ill e

nsur

e th

at c

ontin

ued

fund

ing

from

the

Nat

iona

l Ins

titut

e fo

r H

ealth

Res

earc

h fo

r B

iom

edic

al R

esea

rch

Cen

tres

, Bio

med

ical

Res

earc

h U

nits

and

Clin

ical

R

esea

rch

Faci

litie

s w

ill b

e pa

rtly

con

tinge

nt o

n de

mon

stra

ble

wor

king

with

indu

stry

.

(d)

The

Gov

ernm

ent

will

exp

lore

whi

ch m

echa

nism

s ar

e m

ost

effe

ctiv

e in

enc

oura

ging

stu

dent

s to

stu

dy t

hose

sub

ject

s th

at m

eet

empl

oyer

dem

and

and

natio

nal p

riorit

ies.

For

exa

mpl

e, it

will

w

ork

with

HE

Is a

nd li

fe s

cien

ces

empl

oyer

s to

off

er b

ette

r in

form

atio

n, a

dvic

e an

d gu

idan

ce

abou

t co

urse

con

tent

, gra

duat

e de

stin

atio

ns a

nd h

ow u

nive

rsiti

es li

nk u

p w

ith e

mpl

oyer

s (e

.g.

thro

ugh

wor

k pl

acem

ents

). Th

is is

one

of

the

way

s th

at s

tude

nts

will

be

able

to

acce

ss t

he

oppo

rtun

ities

the

life

sci

ence

s in

dust

ry o

ffer

s th

em.

(a) B

y N

ovem

ber

2009

(b

) To

be d

raft

ed

by O

ctob

er

2009

. To

be

impl

emen

ted

by

early

201

0

(c) A

lread

y un

derw

ay

(d) 2

010

(a) B

IS/D

H

(b) O

SC

HR

(c

) DH

/N

IHR

(d) B

IS

N/A

N

/A

N/A

The

Med

ical

Res

earc

h C

ounc

il w

ill la

unch

a £

3.5

mill

ion

flags

hip

prog

ram

me

in c

linic

al p

harm

acol

ogy

and

path

olog

y, e

nhan

cing

pro

fess

iona

l ski

lls a

nd d

rivin

g co

llabo

ratio

n w

ith in

dust

ry.

In e

arly

201

0M

RC

£3.5

m

36


Po

licy

Mea

sure

By

wh

en?

Wh

o?

Bu

dg

et

AC

CE

SS

TO

FIN

AN

CE

AN

D S

TIM

ULA

TIN

G IN

VE

ST

ME

NT

The

Gov

ernm

ent

anno

unce

d th

e cr

eatio

n of

a U

K In

nova

tion

Inve

stm

ent

Fund

to

inve

st in

te

chno

logy

-bas

ed b

usin

esse

s w

ith h

igh-

grow

th p

oten

tial.

The

new

Fun

d w

ill f

ocus

on

inve

stin

g in

gro

win

g sm

all b

usin

esse

s, s

tart

-ups

and

spi

n-ou

ts in

fou

r hi

gh-t

ech

sect

ors,

incl

udin

g th

e lif

e sc

ienc

es. T

he G

over

nmen

t w

ill in

vest

£15

0 m

illio

n al

ongs

ide

priv

ate

sect

or in

vest

men

t on

an

equa

l ba

sis,

with

the

aim

of

leve

ragi

ng e

noug

h pr

ivat

e in

vest

men

t to

bui

ld a

£1b

n, 1

0-ye

ar V

entu

re C

apita

l Fu

nd.

Ann

ounc

ed 2

9 Ju

ne 2

009

BIS

/DH

/D

EC

C£1

50m

The

Gov

ernm

ent

alre

ady

ince

ntiv

ises

inno

vativ

e ac

tivity

thr

ough

the

tax

sys

tem

. Bud

get

2009

an

noun

ced

that

the

Gov

ernm

ent

wou

ld c

onsi

der

evid

ence

for

fur

ther

cha

nges

to

the

way

the

tax

sy

stem

enc

oura

ges

inno

vativ

e ac

tivity

, to

ensu

re t

he o

ngoi

ng c

ompe

titiv

enes

s of

the

UK

.

The

Gov

ernm

ent

is c

omm

itted

to

ensu

ring

the

UK

rem

ains

an

attr

activ

e lo

catio

n fo

r in

vest

men

t in

inno

vativ

e ac

tivity

. The

wor

k is

exa

min

ing

the

role

of

busi

ness

tax

in e

ncou

ragi

ng in

vest

men

t in

in

nova

tion,

and

the

impa

ct o

n jo

bs a

nd p

rodu

ctiv

ity g

row

th in

the

UK

. It

is a

lso

cons

ider

ing

how

the

U

K t

ax s

yste

m c

ompa

res

to o

ther

reg

imes

inte

rnat

iona

lly, a

nd t

he r

ole

that

tax

es p

lay

in d

ecis

ions

on

whe

re t

o lo

cate

inno

vativ

e in

vest

men

t, in

clud

ing

the

loca

tion

of d

edic

ated

R&

D a

nd m

anuf

actu

ring

cent

res,

and

pat

ent

deve

lopm

ent.

Thi

s as

sess

men

t w

ill a

llow

the

Gov

ernm

ent

to e

nsur

e th

at t

he t

ax

syst

em p

rovi

des

the

appr

opria

te c

ondi

tions

for

inve

stm

ent

in in

nova

tion

and

to d

rive

prod

uctiv

ity,

grow

th a

nd jo

bs.

Inve

stm

ent

in in

nova

tion

occu

rs a

cros

s a

dive

rse

rang

e of

act

iviti

es a

nd s

ecto

rs. S

ince

the

Bud

get

anno

unce

men

t, H

M T

reas

ury,

alo

ng w

ith t

he D

epar

tmen

t fo

r B

usin

ess,

Inno

vatio

n an

d S

kills

, has

m

et w

ith b

usin

esse

s ac

ross

a w

ide

rang

e of

sec

tors

, inc

ludi

ng t

he li

fe s

cien

ces,

to

gath

er e

vide

nce

on in

nova

tion

and

the

role

of

taxa

tion.

Bus

ines

ses

have

hig

hlig

hted

tha

t, a

cros

s m

any

inno

vativ

e ac

tiviti

es, t

he s

tren

gth

of t

he s

cien

ce

and

skill

s ba

se is

the

prim

ary

driv

er o

f in

vest

men

t de

cisi

ons.

The

UK

is s

tron

g in

the

se a

nd o

ther

ke

y fa

ctor

s, s

uch

as t

he r

egul

ator

y an

d le

gal e

nviro

nmen

t. T

axat

ion

can

also

pla

y an

impo

rtan

t ro

le in

inve

stm

ent

deci

sion

s an

d a

com

petit

ive

rate

of

corp

orat

ion

tax,

as

wel

l as

a re

gim

e th

at

prov

ides

cer

tain

ty a

nd m

inim

izes

com

plex

ity f

or a

ll bu

sine

sses

is s

een

as in

crea

sing

ly im

port

ant

by

busi

ness

es.

Pre

-Bud

get

Rep

ort

HM

TN

/A

37


37

Po

licy

Mea

sure

By

wh

en?

Wh

o?

Bu

dg

et

The

wor

k is

con

side

ring

whe

ther

the

re is

sco

pe t

o im

prov

e or

enh

ance

the

way

the

tax

sys

tem

en

cour

ages

inno

vatio

n. M

any

busi

ness

es h

ave

poin

ted

to t

he a

ttra

ctiv

enes

s of

cou

ntrie

s of

ferin

g lo

w c

orpo

ratio

n ta

x ra

tes,

par

ticul

arly

whe

re t

hey

are

able

to

mat

ch t

he U

K in

pro

vidi

ng a

ski

lled

wor

kfor

ce a

nd b

usin

ess-

frie

ndly

env

ironm

ent.

The

refo

re t

he b

enefi

ts o

f in

trod

ucin

g or

enh

anci

ng

spec

ific

tax

relie

fs a

nd in

cent

ives

will

be

set

agai

nst

the

bene

fits

of f

urth

er r

educ

tions

in t

he r

ate

of

corp

orat

ion

tax,

whi

ch t

he G

over

nmen

t co

ntin

ues

to k

eep

unde

r re

view

.

Thes

e di

scus

sion

s ar

e fo

cusi

ng o

n th

e en

tire

inno

vatio

n ch

ain:

the

cre

atio

n of

val

ue, i

nclu

ding

re

sear

ch a

nd d

evel

opm

ent;

sec

urin

g th

at v

alue

, suc

h as

thr

ough

pat

ents

and

oth

er in

telle

ctua

l pr

oper

ty; a

nd u

nloc

king

val

ue, i

nclu

ding

thr

ough

pro

duct

ion

or li

cens

ing.

Thi

s ch

ain

of a

ctiv

ity is

gl

obal

and

can

invo

lve

a ra

nge

of a

ctor

s ar

ound

the

wor

ld. T

he w

ork

is a

sses

sing

the

str

engt

h of

lin

ks b

etw

een

thes

e ac

tiviti

es a

nd t

he b

alan

ce b

etw

een

tax

and

non-

tax

fact

ors

in d

rivin

g in

vest

men

t de

cisi

ons.

Ther

e is

str

ong

supp

ort

amon

g al

l bus

ines

ses

for

the

curr

ent

R&

D t

ax c

redi

ts, p

artic

ular

ly a

mon

g S

ME

s w

here

the

cre

dit

is s

een

as c

ritic

al in

sup

port

ing

cash

flow

. The

re is

evi

denc

e to

sup

port

the

ef

fect

iven

ess

of s

uch

ince

ntiv

es in

incr

easi

ng t

he le

vel o

f R

&D

and

the

wor

k is

see

king

to

ensu

re

the

impa

ct o

f th

e cr

edits

is m

axim

ised

.

Som

e bu

sine

sses

hav

e hi

ghlig

hted

tax

reg

imes

intr

oduc

ed in

som

e E

U M

embe

r S

tate

s in

rec

ent

year

s th

at p

rovi

de a

pre

fere

ntia

l rat

e of

tax

on

inco

me

earn

ed f

rom

inte

llect

ual p

rope

rty,

for

exa

mpl

e “p

aten

t bo

xes”

. HM

Tre

asur

y is

exp

lorin

g th

e ex

tent

to

whi

ch s

uch

sche

mes

cou

ld e

ncou

rage

in

telle

ctua

l pro

pert

y to

be

loca

ted

in t

he U

K a

nd t

he im

pact

thi

s co

uld

have

by

way

of

addi

tiona

l and

pr

oduc

tive

inve

stm

ent

in t

he U

K.

In e

valu

atin

g pr

opos

als

for

chan

ge, e

vide

nce

on t

he lo

ng-t

erm

impa

ct o

n pr

oduc

tivity

and

em

ploy

men

t w

ill b

e cr

ucia

l. Th

e po

tent

ial i

mpa

ct o

n ta

x re

ceip

ts in

the

sho

rt- a

nd lo

ng-t

erm

will

als

o be

a k

ey f

acto

r in

the

ass

essm

ent.

Thi

s w

ill d

raw

on

anal

ysis

of

the

full

cost

s of

intr

oduc

ing

any

chan

ges,

tak

ing

into

acc

ount

any

cur

rent

pre

ssur

es o

n th

e ta

x ba

se. A

ny p

oten

tial c

hang

es w

ill a

lso

be c

onsi

dere

d al

ongs

ide

the

Gov

ernm

ent’s

wid

er a

ppro

ach

to b

usin

ess

taxa

tion,

incl

udin

g pr

ovid

ing

cert

aint

y an

d st

abili

ty a

nd m

inim

izin

g co

mpl

exity

, as

wel

l as

mee

ting

inte

rnat

iona

l com

mitm

ents

.

38


Po

licy

Mea

sure

By

wh

en?

Wh

o?

Bu

dg

et

The

evid

ence

will

be

asse

ssed

ove

r th

e su

mm

er, d

raw

ing

on t

he e

xper

tise

of t

he B

usin

ess-

Gov

ernm

ent

Foru

m o

n Ta

x an

d G

loba

lisat

ion,

as

wel

l as

thro

ugh

furt

her

disc

ussi

ons

with

bus

ines

ses

and

the

wid

er in

nova

tion

com

mun

ity. H

M T

reas

ury

will

set

out

its

asse

ssm

ent

and

prop

osed

ap

proa

ch b

efor

e th

e 20

09 P

re-B

udge

t R

epor

t. If

pro

posa

ls c

an b

e de

velo

ped

that

mee

t th

e co

nsid

erat

ions

set

out

abo

ve, G

over

nmen

t w

ould

con

sult

wid

ely

with

bus

ines

ses

befo

re m

akin

g an

y ch

ange

s.

As

with

all

area

s of

tax

, the

Tre

asur

y ke

eps

this

[Con

sort

ium

Rel

ief]

und

er r

evie

w, a

nd w

ill c

onsi

der

the

case

for

any

cha

nges

.O

ngoi

ngH

MT

N/A

A p

acka

ge o

f m

easu

res

to d

rive

inno

vativ

e pr

ocur

emen

t:

(a)

The

Nat

iona

l Inn

ovat

ion

Cen

tre

(NIC

) hel

d fiv

e N

HS

/indu

stry

“W

ould

n’t

It B

e G

reat

If…

. (W

IBG

I)”

wor

ksho

ps a

t th

e N

HS

Inno

vatio

n E

xpo

in J

une

2009

. The

wor

ksho

ps f

ocus

ed o

n ca

rdia

c ca

re,

urol

ogy,

pae

diat

rics,

am

bula

nce

serv

ices

, and

reg

ener

ativ

e m

edic

ine,

whi

ch g

ener

ated

a s

hort

-lis

t of

opp

ortu

nitie

s fo

r th

e N

HS

. The

NIC

, wor

king

join

tly w

ith t

he S

trat

egic

Hea

lth A

utho

ritie

s (S

HA

s), t

he T

echn

olog

y S

trat

egy

Boa

rd, a

nd K

now

ledg

e Tr

ansf

er N

etw

orks

, will

laun

ch a

ser

ies

of S

mal

l Bus

ines

s R

esea

rch

Initi

ativ

e (S

BR

I) co

mpe

titio

ns t

o en

gage

indu

stry

and

the

NH

S. O

ver

the

next

12

mon

ths,

the

NIC

will

sup

port

a r

ollin

g se

ries

of c

oord

inat

ed S

BR

I ini

tiativ

es t

hat

star

t w

ith N

HS

clin

icia

ns d

efini

ng t

heir

clin

ical

nee

ds, a

nd e

nd w

ith in

dust

ry e

ngag

ing

with

the

NH

S t

o de

velo

p co

mpe

lling

sol

utio

ns; a

nd

(b)

The

new

SH

A D

eliv

ery

Gro

up w

ill le

ad w

ork

to d

evel

op a

n N

HS

SB

RI p

rosp

ectu

s th

at w

ill s

et o

ut

futu

re n

eeds

in k

ey h

ealth

care

are

as. T

he G

roup

will

als

o ho

ld a

n an

nual

con

fere

nce

to b

ette

r un

ders

tand

the

pot

entia

l of

indu

stry

to

prov

ide

solu

tions

.

(a) B

egin

ning

in

Sep

tem

ber

2009

(b

) Fur

ther

de

tails

and

tim

etab

les

will

be

set

out

by

Nov

embe

r 20

09

DH

/NH

S

N/A

39


Po

licy

Mea

sure

By

wh

en?

Wh

o?

Bu

dg

et

To s

uppo

rt t

his

grow

ing

and

stra

tegi

cally

impo

rtan

t in

dust

ry, t

he T

echn

olog

y S

trat

egy

Boa

rd w

ill

laun

ch a

n £1

8 m

illio

n “R

egen

Med

” pr

ogra

mm

e of

inve

stm

ent

to s

uppo

rt k

ey a

reas

of

com

mer

cial

R

&D

and

the

dev

elop

men

t of

R&

D p

artn

ersh

ips.

The

pro

gram

me

will

be

deve

lope

d in

par

tner

ship

w

ith t

he M

edic

al R

esea

rch

Cou

ncil,

the

Eng

inee

ring

and

Phy

sica

l Sci

ence

s R

esea

rch

Cou

ncil,

and

th

e B

iote

chno

logy

and

Bio

logi

cal S

cien

ces

Res

earc

h C

ounc

il w

ho w

ill p

rovi

de a

dditi

onal

fun

ding

of

at

leas

t £3

.5 m

illio

n. P

rogr

amm

e de

velo

pmen

t w

ill b

e gu

ided

by

a hi

gh-le

vel i

ndus

tria

lly-f

ocus

sed

grou

p co

mpr

isin

g in

dust

ry a

nd a

cade

mic

exp

erts

.

The

prog

ram

me

will

hav

e th

ree

stra

nds:

(i)

Reg

ener

ativ

e m

edic

ine

prod

uct

deve

lopm

ent

and

valid

atio

n;

(ii)

Gra

nd c

halle

nges

in u

nder

pinn

ing

tool

s an

d te

chno

logi

es; a

nd

(iii)

Und

erst

andi

ng v

alue

sys

tem

s an

d bu

sine

ss m

odel

s ne

cess

ary

for

the

deliv

ery

of r

egen

erat

ive

med

icin

es.

The

Tech

nolo

gy S

trat

egy

Boa

rd h

as a

lso

com

mitt

ed t

o in

crea

se it

s ex

pert

ise

in t

he li

fe s

cien

ces.

To b

e la

unch

ed

in S

epte

mbe

r 20

09

TSB

and

M

RC

, E

PS

RC

, B

BS

RC

TSB

: £18

m

MR

C, E

PS

RC

an

d B

BS

RC

: £3

.5m

MA

RK

ET

ING

UK

LIF

E S

CIE

NC

ES

A p

acka

ge o

f m

easu

res

will

ens

ure

inte

rnat

iona

l aw

aren

ess:

(a)

UK

Tra

de a

nd In

vest

men

t (U

KTI

) will

coo

rdin

ate

a se

ries

of h

igh-

leve

l eve

nts

over

seas

, beg

inni

ng

with

a U

S t

our

by a

sen

ior

UK

del

egat

ion

to e

ngag

e w

ith k

ey U

S b

ased

life

sci

ence

s co

mpa

nies

an

d in

crea

se t

heir

inve

stm

ent

in t

he U

K.

(b)

UK

TI w

ill in

vest

£1

mill

ion

from

the

Str

ateg

ic In

vest

men

t Fu

nd t

o fu

rthe

r pr

omot

e th

e U

K a

nd

NH

S b

rand

at

flags

hip

life

scie

nces

eve

nts

in t

he U

K a

nd o

vers

eas.

For

exa

mpl

e, a

t A

dvaM

ed in

W

ashi

ngto

n in

Oct

ober

200

9, a

nd a

t M

edic

a in

Düs

seld

orf

in N

ovem

ber

2009

. In

addi

tion,

UK

TI

will

hol

d a

new

hig

h-le

vel t

echn

olog

y pa

rtne

ring

even

t la

ter

in 2

010

that

will

brin

g lif

e sc

ienc

es

deci

sion

-mak

ers

to t

he U

K.

(a) S

umm

er

2009

(b) B

y M

arch

20

11

UK

TI

(a) N

/A

(b) £

1m S

IF

inve

stm

ent

40


Po

licy

Mea

sure

By

wh

en?

Wh

o?

Bu

dg

et

The

OLS

and

UK

TI w

ill h

old

a se

ries

of r

oads

how

s th

roug

hout

the

Eng

lish

regi

ons

and

Dev

olve

d A

dmin

istr

atio

ns. T

hese

roa

dsho

ws

will

brin

g to

geth

er b

usin

esse

s w

ith o

ther

key

reg

iona

l st

akeh

olde

rs t

o:

(i)

Dis

cuss

the

Blu

eprin

t co

mm

itmen

ts a

nd n

ext

step

s to

impl

emen

t th

em; a

nd

(ii)

Hel

p en

sure

the

UK

life

sci

ence

s in

dust

ry s

peak

s w

ith o

ne c

onsi

sten

t vo

ice

in it

s gl

obal

m

arke

ting

activ

ities

Sep

tem

ber

2009

onw

ards

UK

TITB

C

Spe

cial

ists

will

mee

t w

ith c

orpo

rate

ven

ture

fun

ds t

o bu

ild u

pon

the

stro

ng f

ound

atio

ns p

rovi

ded

by

the

UK

Inno

vatio

n In

vest

men

t Fu

nd a

nd a

ttra

ct a

dditi

onal

inve

stm

ent

in t

he U

K.

From

Sum

mer

20

09

UK

TIN

/A

The

UK

will

for

m s

trat

egic

alli

ance

s w

ith k

ey U

S li

fe s

cien

ces

clus

ters

in li

ne w

ith p

ropo

sals

for

a U

K

Life

Sci

ence

s S

uper

Clu

ster

(see

cha

pter

3).

This

will

be

pilo

ted

by c

olla

bora

tion

betw

een

Bos

ton

and

the

gold

en t

riang

le (L

ondo

n, C

ambr

idge

and

Oxf

ord)

, beg

inni

ng w

ith t

he s

igni

ng o

f a

Mem

oran

dum

of

Und

erst

andi

ng.

MoU

to

be

sign

ed in

O

ctob

er 2

009

UK

TIN

/A

42

Pillar 1 – The NHS as an innovation champion

Dr David J. Brickwood (Chair) Vice President of Government Affairs, Europe Johnson and Johnson

Dr Nick Deaney Director of Clinical Research MSD

Dr David Gillen Head of Medical Primary Care Business Unit Pfizer

Simon Jose General Manager and Senior Vice President GSK

Dr Paul Catchpole Head of UK Operations Roche

Dr Bryn Jackson Associate Medical Director UCB

Steve Bates UK Government Relations Director Genzyme

Mick Boroff Director of Strategic Health Outcomes DePuy

Simon Cartmell Chief Executive Apatech

Mark Samuels Director of Business Development Roche Diagnostics

Dr Richard Ascroft Manager, Federal Affairs Lilly

Annex

Membership of the Office for Life Sciences working groups

43

Mike Wallace Director of Health Economics and Reimbursement Johnson and Johnson

Tony Davis Chief Executive Officer Medilinks UK

Dr Mark McIntyre Director Boston Scientific

David Fisher Commercial Director Association of the British Pharmaceutical Industry

Dr Virginia Acha Government Affairs Manager Pfizer

Pillar 2 – Building a more integrated life sciences industry

Subhanu Saxena (Chair) Chief Executive Officer Novartis

Dr Jeremy Haigh European Head of Research and Development Amgen

Dr Jackie Hunter Senior Vice-President GlaxoSmithKline

Dr Melanie Lee CBE Executive Vice President UCB

Tony Davis Chief Executive Officer Medilinks UK

Oliver Wells Chair, Research and Innovation Policy Group Association of British Healthcare Industries

Dr Clive Dix Chairman Modern Bioscience

Dr Sharon O’Kane Chief Scientific Officer Renovo

44


Denise Pollard-Knight Managing Director Nomura

Dr Richard Torbett Government Affairs Manager Pfizer

Dr Aileen Allsop Vice President Science Policy R&D AstraZeneca

Bettina Fitt General Manager UK & Ireland GE Healthcare

Professor Stephen Smith Principle of the Faculty of Medicine Imperial College and Chief Executive of Imperial College Healthcare NHS Trust

Tony Bradshaw Director BioProcessUK

Dr Malcolm Skingle Director, External Science and Technology, Worldwide Business Development GlaxoSmithKline

Professor Sir Keith Peters Chair of the Global Medical Excellence Cluster

Jim Hagan Chief Executive of the Global Medical Excellence Cluster

Sarah Jones Head of Education Association of the British Pharmaceutical Industry

Louise Leong R&D Policy Association of the British Pharmaceutical Industry

Pillar 3 – Access to finance and stimulating investment

John Aston OBE (Chair) Chief Financial Officer Astex Therapeutics

Dhiren Shah Vice President Global Tax GlaxoSmithKline

45

Membership of the Office for Life Sciences working groups

Kirsty Gaston Senior Tax Manager AstraZeneca

Dr Clive Dix Chairman Modern Biosciences

Dr Richard Torbett Government Affairs Manager Pfizer

Colin Hailey Director in the Business Tax Group Deloitte

Michael Hunt Chief Executive Officer ReNeuron

Simon Cartmell Chief Executive Officer Apatech

Sue Middleton Director Corporate Government Affairs GlaxoSmithKline

Pillar 4 – Marketing UK life sciences

Chris Brinsmead (Chair) UK President AstraZeneca

Roy Johnson Executive Chairman Micrima

Andrew Hotchkiss UK Managing Director Eli Lilly

Dr Jeremy Haigh European Head of Research and Development Amgen

Prof. Mark Ferguson CBE Co-Founder and CEO Renovo

Dr Andy Richards Biotechnology Entrepreneur Cambridge Business Angels

46


Chris Francis Director of the UK India Business Council

Kevin Cox Managing Director GSTS Pathology

Philip Schick Group Managing Director Smiths Medical International

Anthony Bragg Managing Director Chugai Pharma

Dudley Ferguson Managing Director Astellas UK

Peter Keen Corporate Development and Finance Director Serentis Pharma

Trade Associations (involved across all groups)

Dr Richard Barker Director General Association of the British Pharmaceutical Industry

Rachel Cashman Government Affairs Manager Association of the British Pharmaceutical Industry

Aisling Burnand MBE Chief Executive Officer BioIndustry Association

Joseph Wildy Joint Head of Public Affairs BioIndustry Association

Doris-Ann Williams Director General British In Vitro Diagnostics Association

Peter Ellingworth Chief Executive Association of British Healthcare Industries

Andy Taylor Director, Healthcare Policy Association of British Healthcare Industries

Printed in the UK on recycled paper containing a minimum of 75% post consumer waste. Department for Business, Innovation and Skills. www.bis.gov.uk

First published July 2009. © Crown copyright. BIS/0.5k/07/09/NP. URN 09/1072

Life Sciences Blueprint - nursingtimes.net · 2 Life Sciences Blueprint As set out in “Building...

Documents

Transcript of Life Sciences Blueprint - nursingtimes.net · 2 Life Sciences Blueprint As set out in “Building...